Nov 04, 2019
Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830
Oct 28, 2019
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
Oct 14, 2019
Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"
Oct 10, 2019
2019 European Dermatological Congress: La Roche-Posay Presents Its Latest Research On Allergies, Atopic Dermatitis & Acne
Oct 09, 2019
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress
Oct 08, 2019
Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema
Oct 03, 2019
Turn Therapeutics(TM) Closes Series B Round to Fuel Lead Atopic Dermatitis Program Trial and Pipeline Expansion
Oct 01, 2019
The National Eczema Association (NEA) Mobilizes Stakeholders To Expose The "Real" Eczema, A Life-Altering Skin Disease Affecting Over 31 Million Americans
Sep 18, 2019
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
Sep 06, 2019
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Aug 19, 2019
Eczema Impacts Physical and Mental Health of 31M Americans
Aug 06, 2019
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Jul 29, 2019
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs
Jul 25, 2019
Almirall Issues Call For Grant Submissions For Development of New Immunodermatology Therapies
Jul 24, 2019
Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products
Jun 28, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Jun 11, 2019
Newly Published Research Shows CLn® BodyWash Significantly Improves Moderate-to-Severe Atopic Dermatitis in Infants, Children and Adolescents
Jun 11, 2019
Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022
Jun 10, 2019
Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials